CollPlant Biotechnologies (CLGN) Total Current Liabilities (2017 - 2026)

CollPlant Biotechnologies has reported Total Current Liabilities for 10 years, with the latest figure at $2.4 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities fell 9.56% year-over-year to $2.4 million; the trailing twelve-month figure through Mar 2026 stood at $2.4 million (down 9.56% YoY), and the FY2025 full-year result was $2.7 million, down 10.03% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $2.4 million, down from $2.7 million in the prior quarter.
• The five-year high for Total Current Liabilities was $3.4 million in Q1 2024, with the low at $2.3 million in Q3 2022.
• Historically, Total Current Liabilities has averaged $2.8 million across 5 years, with a median of $2.7 million in 2025.
• Annual changes were most pronounced in 2022 — Total Current Liabilities decreased 22.65% — and 2023, when it rose 17.83%.
• CollPlant Biotechnologies' Total Current Liabilities stood at $3.1 million in 2022, then rose by 4.7% to $3.3 million in 2023, then slipped by 8.64% to $3.0 million in 2024, then fell by 10.03% to $2.7 million in 2025, then declined by 8.61% to $2.4 million in 2026.
• The last three Total Current Liabilities figures came in at $2.4 million (Q1 2026), $2.7 million (Q4 2025), and $2.6 million (Q3 2025), per Business Quant data.